BF0801, a novel adenine derivative, inhibits platelet activation via phosphodiesterase inhibition and P2Y₁₂ antagonism

Summary

Though antiplatelet drugs are proven beneficial to patients with coronary heart disease and stroke, more effective and safer antiplatelet drugs are still needed. In this study we report the antiplatelet effects and mechanism of BF0801, a novel adenine derivative. BF0801 dramatically inhibited platelet aggregation and ATP release induced by ADP, 2MeSADP, AYPGKF, SFLLRN or convulxin without affecting shape change in vitro. It also potentiated the inhibitory effects of adenosine-based P2Y₁₂ antagonist AR-C69931MX or phosphodiesterase (PDE) inhibitor IBMX on platelet aggregation. The cAMP levels in both resting and forskolin-stimulated platelets were increased by BF0801 suggesting its PDE inhibitor activity, which is further confirmed by the concentration-dependent suppression of BF0801 on the native and recombinant PDE. Similar to AR-C69931MX, BF0801 drastically inhibited 2MeSADP-induced adenylyl cyclase inhibition in platelets indicating its P2Y₁₂ antagonism activity, which is substantiated by the inhibition of BF0801 on the interaction between ADP and P2Y₁₂ receptor expressed in CHO-K1 cells measured by atomic force microscopy. Moreover, we confirmed the antiplatelet effects of BF0801 using platelets from rats intravenously given BF0801. In summary, for the first time we developed a novel adenine derivative bearing dual activities of PDE inhibition and P2Y₁₂ antagonism, which may have therapeutic advantage as a potential antithrombotic drug.

Keywords

Antiplatelet - adenine derivative - cAMP - P2Y₁₂ - phosphodiesterase

• References

• 1 Zurn CS, Geisler T, Gawaz M. ADP-receptor blockade: A case for personalised pharmacotherapy?. Thromb Haemost 2010; 103: 496-506.
• 2 Han Y, Li Y, Wang S. et al. Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study. Am Heart J 2009; 157: 733-739.
• 3 Daniel JL, Dangelmaier C, Jin J. et al. Molecular basis for ADP-induced platelet activation. I. Evidence for three distinct ADP receptors on human platelets. J Biol Chem 1998; 273: 2024-2029.
• 4 Jin J, Daniel JL, Kunapuli SP. Molecular basis for ADP-induced platelet activation. II. The P2Y1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets. J Biol Chem 1998; 273: 2030-2034.
• 5 Barrabes JA, Inserte J, Mirabet M. et al. Antagonism of P2Y₁₂ or GPIIb/IIIa receptors reduces platelet-mediated myocardial injury after ischaemia and reperfusion in isolated rat hearts. Thromb Haemost 2010; 104: 128-135.
• 6 Dorsam RT, Kunapuli SP. Central role of the P2Y₁₂ receptor in platelet activation. J Clin Invest 2004; 113: 340-345.
• 7 Jin J, Kunapuli SP. Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation. Proc Natl Acad Sci USA 1998; 95: 8070-8074.
• 8 Zu L, Jiang H, He J. et al. Salicylate blocks lipolytic actions of tumor necrosis factor-alpha in primary rat adipocytes. Mol Pharmacol 2008; 73: 215-223.
• 9 Foster CJ, Prosser DM, Agans JM. et al. Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs. J Clin Invest 2001; 107: 1591-1598.
• 10 Liu J, Joglekar M, Ware J. et al. Evaluation of the physiological significance of botrocetin/ von Willebrand factor in vitro signaling. J Thromb Haemost 2008; 6: 1915-1922.
• 11 Shankar H, Murugappan S, Kim S. et al. Role of G protein-gated inwardly-rectifying potassium channels in P2Y₁₂ receptor-mediated platelet functional responses. Blood 2004; 104: 1335-1343.
• 12 Ding Z, Bynagari YS, Mada SR. et al. Studies on the role of the extracellular cysteines and oligomeric structures of the P2Y receptor when interacting with antagonists. J Thromb Haemost 2009; 7: 232-234.
• 13 Ding ZR, Huang SJ, Sun JJ. Induction of platelet activation by cobra venom factor from Naja naja atra in rat. Acta Pharmacol Sin 2000; 21: 649-654.
• 14 Liu J, Pestina TI, Berndt MC. et al. The roles of ADP and TXA in botrocetin/VWF-induced aggregation of washed platelets. J Thromb Haemost 2004; 2: 2213-2222.
• 15 Shankar H, Kahner BN, Prabhakar J. et al. G-protein-gated inwardly rectifying potassium channels regulate ADP-induced cPLA2 activity in platelets through Src family kinases. Blood 2006; 108: 3027-3034.
• 16 Ding Z, Kim S, Kunapuli SP. Identification of a potent inverse agonist at a constitutively active mutant of human P2Y₁₂ receptor. Mol Pharmacol 2006; 69: 338-345.
• 17 Ma T, Zhu X. Interleukin-6 increases the levels of cyclic GMP and nitrite in rat hippocampal slices. Eur J Pharmacol 1997; 321: 343-347.
• 18 Spoto G, Whitehead E, Ferraro A. et al. A reverse-phase HPLC method for cAMP phosphodiesterase activity. Analyt Biochem 1991; 196: 207-210.
• 19 Tang HF, Song YH, Chen JC. et al. Upregulation of phosphodiesterase-4 in the lung of allergic rats. Am J Resp Crit Care Med 2005; 171: 823-828.
• 20 Horber JK, Miles MJ. Scanning probe evolution in biology. Science (NY) 2003; 302: 1002-1005.
• 21 Hinterdorfer P, Dufrene YF. Detection and localization of single molecular recognition events using atomic force microscopy. Nature Methods 2006; 3: 347-355.
• 22 Quinton TM, Ozdener F, Dangelmaier C. et al. Glycoprotein VI-mediated platelet fibrinogen receptor activation occurs through calcium-sensitive and PKC-sensitive pathways without a requirement for secreted ADP. Blood 2002; 99: 3228-3234.
• 23 Kim S, Foster C, Lecchi A. et al. Protease-activated receptors 1 and 4 do not stimulate G(i) signaling pathways in the absence of secreted ADP and cause human platelet aggregation independently of G(i) signaling. Blood 2002; 99: 3629-3636.
• 24 Atkinson BT, Stafford MJ, Pears CJ. et al. Signalling events underlying platelet aggregation induced by the glycoprotein VI agonist convulxin. Eur J Biochem / FEBS 2001; 268: 5242-5248.
• 25 Ingall AH, Dixon J, Bailey A. et al. Antagonists of the platelet P2T receptor: a novel approach to antithrombotic therapy. J Med Chem 1999; 42: 213-220.
• 26 Liu FC, Liao CH, Chang YW. et al. A new insight of anti-platelet effects of sirtinol in platelets aggregation via cyclic AMP phosphodiesterase. Biochem Pharmacol 2009; 77: 1364-1373.
• 27 Omori K, Kotera J. Overview of PDEs and their regulation. Circ Res 2007; 100: 309-327.
• 28 Sun B, Li H, Shakur Y. et al. Role of phosphodiesterase type 3A and 3B in regulating platelet and cardiac function using subtype-selective knockout mice. Cell Signal 2007; 19: 1765-1771.
• 29 Podzuweit T, Nennstiel P, Muller A. Isozyme selective inhibition of cGMP-stimulated cyclic nucleotide phosphodiesterases by erythro-9-(2-hydroxy-3-nonyl) adenine. Cell Signal 1995; 7: 733-738.
• 30 Andre P, Delaney SM, LaRocca T. et al. P2Y₁₂ regulates platelet adhesion/activation, thrombus growth, and thrombus stability in injured arteries. J Clin Invest 2003; 112: 398-406.
• 31 Kim S, Jin J, Kunapuli SP. Akt activation in platelets depends on Gi signaling pathways. J Biol Chem 2004; 279: 4186-4195.
• 32 Hayashi H, Sudo T. Effects of the cAMP-elevating agents cilostamide, cilostazol and forskolin on the phosphorylation of Akt and GSK-3beta in platelets. Thromb Haemost 2009; 102: 327-335.
• 33 Costanzi S, Mamedova L, Gao ZG. et al. Architecture of P2Y nucleotide receptors: structural comparison based on sequence analysis, mutagenesis, and homology modeling. J Med Chem 2004; 47: 5393-5404.
• 34 Humphries RG, Robertson MJ, Leff P. A novel series of P2T purinoceptor antagonists: definition of the role of ADP in arterial thrombosis. Trends Pharmacol Sci 1995; 16: 179-181.
• 35 Florin EL, Moy VT, Gaub HE. Adhesion forces between individual ligand-receptor pairs. Science (NY) 1994; 264: 415-417.
• 36 Zhang X, Craig SE, Kirby H. et al. Molecular basis for the dynamic strength of the integrin alpha4beta1/VCAM-1 interaction. Biophys J 2004; 87: 3470-3478.
• 37 Muller DJ, Helenius J, Alsteens D. et al. Force probing surfaces of living cells to molecular resolution. Nature Chem Biol 2009; 5: 383-390.
• 38 Helenius J, Heisenberg CP, Gaub HE. et al. Single-cell force spectroscopy. J Cell Sci 2008; 121: 1785-1791.
• 39 Zhang X, Chen A, De Leon D. et al. Atomic force microscopy measurement of leukocyte-endothelial interaction. Am J Physiol 2004; 286: H359-367.
• 40 Lee I, Marchant RE. Molecular interaction studies of hemostasis: fibrinogen ligand-human platelet receptor interactions. Ultramicroscopy 2003; 97: 341-352.
• 41 Cattaneo M, Lecchi A. Inhibition of the platelet P2Y₁₂ receptor for adenosine diphosphate potentiates the antiplatelet effect of prostacyclin. J Thromb Haemost 2007; 5: 577-582.
• 42 Dickinson NT, Jang EK, Haslam RJ. Activation of cGMP-stimulated phosphodiesterase by nitroprusside limits cAMP accumulation in human platelets: effects on platelet aggregation. Biochem J 1997; 323: 371-377.
• 43 Ishii H, Kojima Y, Masuda Y. et al. Expression of thrombin-activatable fibrinolysis inhibitor (TAFI) is up-regulated by increase in intracellular cyclic AMP levels in cultured HepG2 cells. Thromb Haemost 2009; 102: 1204-1211.
• 44 Lee SW, Park SW, Yun SC. et al. Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: Drug-Eluting stenting followed by Cilostazol treatment REduces Adverse Serious cardiac Events (DECREASE registry). Am Heart J 2010; 159: 284-291e1.
• 45 Jeong YH, Lee SW, Choi BR. et al. Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study. J Am Coll Cardiol 2009; 53: 1101-1109.
• 46 Lee JM, Park S, Shin DJ. et al. Relation of genetic polymorphisms in the cytoch-rome P450 gene with clopidogrel resistance after drug-eluting stent implantation in Koreans. Am J Cardiol 2009; 104: 46-51.